Guggenheim downgraded Mersana Therapeutics to Neutral from Buy based on the “disappointing” UPLIFT clinical trial results for upifitamab rilsodotin, or UpRi, and “lingering safety concerns.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRSN:
- Mersana Faces Catastrophe After Test Flub
- Mersana (NASDAQ:MRSN) Nosedives after Ovarian Cancer Trial Disappoints
- Mersana Therapeutics provides strategic reprioritization, financial update
- Mersana Therapeutics’ UPLIFT trial ‘failed to replicate’ previous efficacy data
- Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization